Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TCL1B |
| Gene Name: | TCL1B |
| Protein Full Name: | T-cell leukemia/lymphoma protein 1B |
| Alias: | Oncogene TCL-1B;SYN-1;Syncytiotrophoblast-specific protein;TCL1/MTCP1-like protein 1 |
| Mass (Da): | 14846 |
| Number AA: | 128 |
| UniProt ID: | O95988 |
| Locus ID: | 9623 |
| COSMIC ID: | TCL1B |
| Gene location on chromosome: | 14q32.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.24 |
| Deregulated in translocations: | t(14;14)(q11;q32.1) that causes a TCRalpha/delta-TCL1A/TCL1B fusion protein |
| Normal role description: | TCL1B is thought to enhance the phosphorylation and activation of AKT1 and AKT2. It is expressed in rare T-cell leukemias with the translocation, t(14;14)(q11;q32.1), that causes a TCRalpha/delta-TCL1A/TCL1B fusion protein. Though TCL1A upregulation by the similar chromosomal rearrangement is critical in the oncogenesis of T-cell prolymphocytic leukemia, TCL1B role in oncogenesis is unknown. Since AKT is a potent inhibitor of MDM2, an anti-apoptotic protein, then the activation of AKT by TCL1B could contribute to oncogenesis. |